LB Pharmaceuticals, Inc.

Compare

8 Followers

LBRX Stock Chart & Stats

$16.28

Market closed

$16.28

Day’s Range― - ―

52-Week Range$13.36 - $20.25

Previous CloseN/A

VolumeN/A

Average Volume (3M)347.37K

Market Cap

N/A

Enterprise ValueN/A

Total Cash (Recent Filing)$72.13M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta-1.00

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding22,442,990

10 Day Avg. Volume178,624

30 Day Avg. Volume347,371

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)-0.65

Price to Sales (P/S)0.00

P/FCF Ratio-1.14

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

$46.33

Price Target Upside184.58% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

Bulls Say, Bears Say

Bulls Say

Clinical Trials And DevelopmentThe successful ph2 study of LB-102 in schizophrenia demonstrated significant separation from placebo on all doses and a favorable safety profile.

Efficacy And SafetyLB-102's novel pharmacology and cleaner safety profile are important differentiators that support its potential for blockbuster sales.

Market PotentialThe enthusiasm for LB-102 is based on its potential to become a blockbuster next-gen antipsychotic for the treatment of schizophrenia and mood disorders.

Bears Say

Clinical Trial RisksKey risks include the potential failure of LB-102 in the Phase 3 trial for schizophrenia.

CompetitionCompeting agents with improved efficacy and safety profiles pose a risk.

LB Pharmaceuticals, Inc. News

LB Pharmaceuticals appoints Rawls as SVP of Regulatory Affairs

LB Pharmaceuticals (LBRX) announced the appointment of James Rawls, Pharm.D., as Senior Vice President, SVP, of Regulatory Affairs....

18d ago

LBRX

Opening Day: Cerebras Systems withdraws IPO filing

Cerebras Systems (CRBS) has withdrawn its IPO filing. In a SEC filing, the company said, in part, “Cerebras...

25d ago

CBK

LB Pharmaceuticals to present posters on Phase 2 NOVA trial of LB-102

LB Pharmaceuticals (LBRX) announced that three posters featuring new and previously reported analyses from its Phase 2 NOVA...

26d ago

LBRX

LB Pharmaceuticals initiated with an Outperform at Leerink

Leerink initiated coverage of LB Pharmaceuticals (LBRX) with an Outperform rating and $34 price target LB-102 is a...

26d ago

LBRX

LB Pharmaceuticals initiated with a Buy at Stifel

Stifel initiated coverage of LB Pharmaceuticals (LBRX) with a Buy rating and $27 price target The firm says...

26d ago

LBRX

LB Pharmaceuticals initiated with an Overweight at Piper Sandler

Piper Sandler initiated coverage of LB Pharmaceuticals (LBRX) with an Overweight rating and $78 price target The firm...

26d ago

LBRX

Buy Rating for LB Pharmaceuticals Driven by Promising LB-102 and Market Potential

LB Pharmaceuticals, Inc. (LBRX) has received a new Buy rating, initiated by Piper Sandler analyst, Yasmeen Rahimi. Yasmeen...

26d ago

LBRX

Promising Prospects for LB Pharmaceuticals: Buy Rating Affirmed on LB-102’s Market Potential

LB Pharmaceuticals, Inc. (LBRX) has received a new Buy rating, initiated by Stifel Nicolaus analyst, Paul Matteis. Paul...

26d ago

LBRX

LB Pharmaceuticals appoints William Kane, Rekha Hemrajani to board

LB Pharmaceuticals (LBRX) announced the appointments of William Kane and Rekha Hemrajani to its Board of Directors effective...

1M ago

LBRX

Opening Day: Klarna jumps in market debut

Shares of Klarna jumped 30% in their highly anticipated market debut, valuing the company at almost $40B. The...

2M ago

ETS

LGN

LBRX FAQ

What was LB Pharmaceuticals, Inc.’s price range in the past 12 months?

LB Pharmaceuticals, Inc. lowest stock price was $13.36 and its highest was $20.25 in the past 12 months.

What is LB Pharmaceuticals, Inc.’s market cap?

Currently, no data Available

When is LB Pharmaceuticals, Inc.’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were LB Pharmaceuticals, Inc.’s earnings last quarter?

Currently, no data Available

Is LB Pharmaceuticals, Inc. overvalued?

According to Wall Street analysts LB Pharmaceuticals, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does LB Pharmaceuticals, Inc. pay dividends?

LB Pharmaceuticals, Inc. does not currently pay dividends.

What is LB Pharmaceuticals, Inc.’s EPS estimate?

LB Pharmaceuticals, Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does LB Pharmaceuticals, Inc. have?

LB Pharmaceuticals, Inc. has 22,442,990 shares outstanding.

What happened to LB Pharmaceuticals, Inc.’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of LB Pharmaceuticals, Inc.?

Currently, no hedge funds are holding shares in LBRX

Company Description

LB Pharmaceuticals, Inc.

Clinical‑stage biopharmaceutical company developing novel therapies for neuropsychiatric diseases (e.g. schizophrenia, bipolar depression). Lead candidate is LB‑102, a methylated derivative of amisulpride.

LBRX Stock 12 Month Forecast

Average Price Target

$46.33

▲(184.58% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"14":"$14","79":"$79","30.25":"$30.3","46.5":"$46.5","62.75":"$62.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":78,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$78.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":46.33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$46.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":27,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$27.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[14,30.25,46.5,62.75,79],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.76,20.54769230769231,25.335384615384616,30.123076923076923,34.91076923076923,39.69846153846154,44.48615384615385,49.27384615384615,54.06153846153846,58.84923076923077,63.636923076923075,68.4246153846154,73.2123076923077,{"y":78,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.76,18.111538461538462,20.463076923076922,22.814615384615383,25.166153846153847,27.517692307692307,29.869230769230768,32.22076923076923,34.57230769230769,36.92384615384615,39.27538461538461,41.62692307692308,43.97846153846154,{"y":46.33,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.76,16.624615384615385,17.48923076923077,18.353846153846153,19.21846153846154,20.083076923076923,20.947692307692307,21.81230769230769,22.676923076923078,23.54153846153846,24.40615384615385,25.270769230769233,26.135384615384616,{"y":27,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":16.8,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":16.8,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":16.8,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":16.8,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":16.8,"date":1740787200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":16.8,"date":1743465600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":16.8,"date":1746057600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":16.8,"date":1748736000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":16.8,"date":1751328000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":16.8,"date":1754006400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":16.8,"date":1756684800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":15.76,"date":1759276800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":15.76,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >